JP2006528236A5 - - Google Patents

Download PDF

Info

Publication number
JP2006528236A5
JP2006528236A5 JP2006530660A JP2006530660A JP2006528236A5 JP 2006528236 A5 JP2006528236 A5 JP 2006528236A5 JP 2006530660 A JP2006530660 A JP 2006530660A JP 2006530660 A JP2006530660 A JP 2006530660A JP 2006528236 A5 JP2006528236 A5 JP 2006528236A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
mammal
disorder
ziprasidone
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006530660A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006528236A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2004/001600 external-priority patent/WO2004100956A1/en
Publication of JP2006528236A publication Critical patent/JP2006528236A/ja
Publication of JP2006528236A5 publication Critical patent/JP2006528236A5/ja
Pending legal-status Critical Current

Links

JP2006530660A 2003-05-16 2004-05-05 ジプラシドンを用いて認知を増強する方法 Pending JP2006528236A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47137903P 2003-05-16 2003-05-16
PCT/IB2004/001600 WO2004100956A1 (en) 2003-05-16 2004-05-05 Method for enhancing cognition using ziprasidone

Publications (2)

Publication Number Publication Date
JP2006528236A JP2006528236A (ja) 2006-12-14
JP2006528236A5 true JP2006528236A5 (https=) 2007-06-21

Family

ID=33452442

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006530660A Pending JP2006528236A (ja) 2003-05-16 2004-05-05 ジプラシドンを用いて認知を増強する方法

Country Status (9)

Country Link
US (2) US20050014764A1 (https=)
EP (1) EP1626722A1 (https=)
JP (1) JP2006528236A (https=)
AR (1) AR044337A1 (https=)
BR (1) BRPI0419067A (https=)
CA (2) CA2625837A1 (https=)
MX (1) MXPA05012325A (https=)
TW (1) TW200507847A (https=)
WO (1) WO2004100956A1 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2323451T7 (es) 2001-07-20 2011-08-01 Psychogenics Inc. Tratamiento para el trastorno de hiperactividad con deficit de atencion.
HUE034290T2 (en) 2003-04-29 2018-02-28 Orexigen Therapeutics Inc Preparations containing opioid antagonist and bupropion to affect weight loss
AR056968A1 (es) * 2005-04-11 2007-11-07 Xenon Pharmaceuticals Inc Compuestos espiro-oxindol y composiciones farmacéuticas
AR053710A1 (es) * 2005-04-11 2007-05-16 Xenon Pharmaceuticals Inc Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
CA2630624C (en) 2005-11-22 2013-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
JP2009524637A (ja) * 2006-01-27 2009-07-02 ファイザー・プロダクツ・インク アミノフタラジン誘導体化合物
EP2520567A3 (en) 2006-02-23 2012-12-12 Shionogi & Co., Ltd. Nitrogen-containing heterocycle derivatives substituted with cyclic group
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
AU2007307635A1 (en) * 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
WO2008060789A2 (en) * 2006-10-12 2008-05-22 Xenon Pharmaceuticals Inc. Use of spiro-oxindole compounds as therapeutic agents
US20110294842A9 (en) * 2006-10-12 2011-12-01 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
EA201070077A1 (ru) * 2007-06-29 2010-08-30 Эмори Юниверсити Антагонисты nmda-рецепторов с нейропротективным действием
JP2011520815A (ja) * 2008-05-09 2011-07-21 エモリー・ユニバーシテイ 精神神経障害治療のためのｎｍｄａ受容体拮抗薬
JP2011521973A (ja) 2008-05-30 2011-07-28 オレキシジェン・セラピューティクス・インコーポレーテッド 内臓脂肪の状態を処置するための方法
JO3032B1 (ar) * 2008-10-17 2016-09-05 Xenon Pharmaceuticals Inc مركبات سبيرو – اوكسندول وإستعمالاتها كعوامل علاجية.
CA2741024A1 (en) * 2008-10-17 2010-04-22 Xenon Pharmaceuticals Inc. Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es) 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
KR20120099429A (ko) 2009-10-14 2012-09-10 제논 파마슈티칼스 인크. 스피로-옥스인돌 화합물의 합성 방법
US20110086899A1 (en) * 2009-10-14 2011-04-14 Xenon Pharmaceuticals Inc. Pharmaceutical compositions for oral administration
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
WO2011106729A2 (en) 2010-02-26 2011-09-01 Xenon Pharmaceuticals Inc. Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
MX2012013197A (es) 2010-05-12 2013-04-03 Abbvie Inc Inhibidores de indazol de cinasa.
LT3730132T (lt) 2012-06-06 2022-08-25 Nalpropion Pharmaceuticals Llc Kompozicija, skirta panaudoti pacientų su didele širdies ir kraujagyslių ligų rizika antsvorio ir nutukimo gydymo būde
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
WO2016127068A1 (en) 2015-02-05 2016-08-11 Teva Pharmaceuticals International Gmbh Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
WO2016191316A1 (en) * 2015-05-22 2016-12-01 Stem Cell Theranostics, Inc. Modulation of drug-induced cardiotoxicity
AU2023235233A1 (en) 2022-03-14 2024-09-12 Slap Pharmaceuticals Llc Multicyclic compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
DK0904273T3 (da) * 1996-05-07 2003-07-07 Pfizer Mesylat-trihydratsalt af 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl-6-chlor-1,3-dihydro-2(1H)-indol-2-on(=ziprasidon), dets fremstilling og dets anvendelse som dipamin D2 antagonist
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
IL125951A (en) * 1997-09-05 2003-09-17 Pfizer Prod Inc A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6387904B2 (en) * 1998-05-18 2002-05-14 Pfizer Inc Method of treating glaucoma and ischemic retinopathy
WO2000059459A1 (en) * 1999-03-30 2000-10-12 Lion Corporation Hairdye composition of single preparation type containing an oxidase
CA2363942A1 (en) * 1999-04-06 2000-10-12 Sepracor Inc. Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites

Similar Documents

Publication Publication Date Title
JP2006528236A5 (https=)
JP2019031502A5 (https=)
JP2007516193A5 (https=)
JP2010529118A5 (https=)
CL2007003690A1 (es) Compuestos derivados de 1-azonia-biciclo[2.2.2]octano; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades pulmonares obstructivas cronicas.
JP2007523049A5 (https=)
JP2011513196A5 (https=)
CA2256227A1 (en) Method of treating psychiatric conditions
MA29098B1 (fr) Compositions pour le traitement du vhc
CL2007001131A1 (es) Compuestos derivados de purina sustituida; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria u obstructiva de las vias respiratorias.
WO2007092329A3 (en) Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
EP1706108A4 (en) TREATMENT OF FAT AND METABOLIC SYNDROME WITH TRANSHINONE DERIVATIVES FOR INCREASING METABOLISM ACTIVITY
JP2004534816A5 (https=)
JP2008526861A5 (https=)
ATE552251T1 (de) Thiophen- und furanverbindungen
JP2018528266A5 (https=)
JP2007516278A5 (https=)
JP2008501778A5 (https=)
JP2005527477A5 (https=)
JP2008513426A5 (https=)
EP1954257A4 (en) METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION
EP1928235A4 (en) COMPOSITION AND METHOD FOR USE IN DISEASES WITH CARTILAGE PARTICIPATION
EP2392336A3 (en) Use of 24-norUDCA
DE602006009556D1 (de) Chinolin-derivate zur behandlung von mglur5-rezeptor-vermittelten erkrankungen
JP2004517948A5 (https=)